JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Stocks · News reference
Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-08-14 AccNo: 0001104659-26-096483 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from